# A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma

> **NCT01569919** · PHASE2 · UNKNOWN · sponsor: **Wales Cancer Trials Unit** · enrollment: 26 (estimated)

## Conditions studied

- Malignant
- Pleural
- Mesothelioma

## Interventions

- **BIOLOGICAL:** TroVax®
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DIETARY_SUPPLEMENT:** Vitamin B12
- **DIETARY_SUPPLEMENT:** Folic Acid
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01569919
- **Lead sponsor:** Wales Cancer Trials Unit
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2014-06
- **Final completion:** 2014-12
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2013-03-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01569919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01569919, "A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01569919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*